Is the train leaving the station?, page-294

The only thing shareholder should be focused on is the breakeven number at EOY which is why 2nd quarter 4c will be crucial. SP will not breakout until the company can prove to the market that it can stand on its own.

If anyone is going to the AGM and feels the same way about how vital the numbers will make or break us in 2018, can someone please ask the following questions.

1. Are we still on track to hit 4.4m in CC sale in q2?

2. Is Admedus still forecasting a breakeven in the q4 with a total revenue of $34m in 2018?

2a - Given the numbers provided in the most recent presentation and q1 4c below, Admedus will not breakeven on a total revenue of 34m and total expenses $48m, is there anything else in the forecast we should know about?

	Column 1	Column 2	Column 3	Column 4	Column 5	Column 6	Column 7	Column 8
0	Admedus 2018 forecast $'000	4th Q 2017 (Actual)	1st Q 2018 (Actual)	2nd Q 2018 (Forecast)	3rd Q 2018 (Forecast)	4th Q 2018 (Forecast)	2018 Total (Forecast)	Comment
1	Sales	6,300	6,200	8,400	9,200	10,200	34,000
2	Adapt	2,100	2,200	4,400	5,200	6,200	18,000	19 April presentation
3	Infusion	4,200	4,000	4,000	4,000	4,000	16,000	19 April presentation
4	Other Income	-	-	-	-	-	-
5	Total revenue	6,300	6,200	8,400	9,200	10,200	34,000
6
7	Cash receipt from operation	6,484	6,776	8,400	9,200	10,200	34,576
8	Cash receipt from Investment	-	-
9	Cash receipt from Grant	-	-
10	Total Cash Receipt	6,484	6,776	8,400	9,200	10,200	34,576
11
12	Operating expenses	9,872	11,565	11,691	11,700	11,700	46,656
13	Investing expenses	420	485	500	500	500	1,985
14	Currency movement		176
15	Total Cash Outgoing	10,292	12,226	12,191	12,200	12,200	48,641
16	Total Cashflow	- 3,808	- 5,450	- 3,791	- 3,000	- 2,000	- 14,065
17
18	Cash at bank*	8,255	7,805	4,014	1,014	- 986		Profile is prior to CR
19	Loan Drawn*		5,000	10,000	10,000	10,000		Profile is prior to CR

*numbers are prior to placement

2b - how is the most recent recuritments going to impact our expense forecast in 2018 given they should be additional cost to the $48m quoted above (given acceleration of products will not increase revenue in 2018)?

Very indicative numbers used in the table above, however this is my number 1 concern for 2018.